Lost in Translation: CRF1 Receptor Antagonists and Addiction Treatment

Affiliations

¹ Behavioral Neuroscience Branch, IRP-NIDA, NIH, Baltimore, MD, USA.
² Department of Psychiatry and Behavioral Neuroscience, University of Chicago, IL, USA.

Comment

Yavin Shaham et al. Neuropsychopharmacology. 2016 Nov.

. 2016 Nov;41(12):2795-2797.

doi: 10.1038/npp.2016.94.

¹ Behavioral Neuroscience Branch, IRP-NIDA, NIH, Baltimore, MD, USA.
² Department of Psychiatry and Behavioral Neuroscience, University of Chicago, IL, USA.

No abstract available

Comment on

The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects.
Schwandt ML, Cortes CR, Kwako LE, George DT, Momenan R, Sinha R, Grigoriadis DE, Pich EM, Leggio L, Heilig M. Schwandt ML, et al. Neuropsychopharmacology. 2016 Nov;41(12):2818-2829. doi: 10.1038/npp.2016.61. Epub 2016 Apr 25. Neuropsychopharmacology. 2016. PMID: 27109623 Free PMC article. Clinical Trial.

1. Bale TL, Vale WW (2004). CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44: 525–557. - PubMed
1. Cole BJ, Cador M, Stinus L, Rivier J, Vale W, Koob GF (1990). Central administration of a CRF antagonist blocks the development of stress-induced behavioral sensitization. Brain Res 512: 343–346. - PubMed
1. Fleck BA, Hoare SR, Pick RR, Bradbury MJ, Grigoriadis DE (2012). Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. J Pharmacol Exp Ther 341: 518–531. - PubMed
1. Grillon C, Hale E, Lieberman L, Davis A, Pine DS, Ernst M (2015). The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle. Neuropsychopharmacology 40: 1064–1071. - PMC - PubMed
1. Heilig M, Epstein DE, Nader M, Shaham Y (2016). It is time to connect: addiction neuroscience and social context. Nat Rev Neurosci. - PMC - PubMed